Workflow
治疗产品
icon
Search documents
速递|刚刚!诺和诺德投资8亿元启动天津生产厂质量检测实验室扩建项目
GLP1减重宝典· 2025-07-09 08:39
Core Viewpoint - Novo Nordisk has signed a memorandum of understanding with the Tianjin Economic Development Zone to invest approximately 800 million yuan in the expansion of a quality testing laboratory at its Tianjin production facility, which is expected to enhance production capacity and ensure high-quality manufacturing [2][4]. Group 1 - The quality testing laboratory expansion project will cover a total area of approximately 18,000 square meters and will include chemical, microbiological, and biological laboratories, with completion planned by the end of 2026 [4]. - Since its establishment, the Novo Nordisk Tianjin production facility has continuously increased investment, with a significant 4 billion yuan investment in a sterile formulation expansion project initiated in March 2024, reflecting the company's commitment to growth in the region [5]. - The cumulative investment in the Tianjin Economic Development Zone by Novo Nordisk has exceeded 10 billion yuan, indicating a strong and ongoing commitment to the local market [5]. Group 2 - Mr. Kang Jian, Global Vice President of Novo Nordisk and President of the Tianjin production facility, expressed gratitude for the support from local government and emphasized that the new laboratory will better ensure future capacity enhancement and high-quality production [7]. - Novo Nordisk, founded in 1923 and headquartered in Denmark, is a leading global biopharmaceutical company with approximately 77,400 employees across 80 countries, providing products and services to around 170 countries [9]. - The Tianjin production facility is a strategic production base for Novo Nordisk, adhering to strict quality management systems and environmental sustainability practices, including the use of 100% renewable wind energy [9].